
Tricida TCDA
Quartalsbericht 2022-Q3
hinzugefügt 14.11.2022
Tricida Langfristige Verbindlichkeiten 2011-2025 | TCDA
Langfristige Verbindlichkeiten Jährlich Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 13.2 M | 68.2 M | 38.5 M | 217 K | 67.1 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 68.2 M | 217 K | 37.4 M |
Langfristige Verbindlichkeiten Vierteljährlich Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 440 K | 483 K | - | 323 K | - | 323 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 483 K | 323 K | 392 K |
Langfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
46.5 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
274 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
104 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.44 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
10.7 M | $ 2.67 | -2.55 % | $ 1.44 B | ||
|
Agile Therapeutics
AGRX
|
16.4 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
3.83 B | - | - | $ 11.5 B | ||
|
Aurora Cannabis
ACB
|
681 M | $ 4.47 | -2.08 % | $ 86.3 M | ||
|
DURECT Corporation
DRRX
|
26.4 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
36.6 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
8.8 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
6.61 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
316 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
38.2 M | - | 2.45 % | $ 38.1 M | ||
|
Emergent BioSolutions
EBS
|
1.02 B | $ 12.36 | -2.37 % | $ 633 M | ||
|
Athenex
ATNX
|
157 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
134 M | $ 21.6 | 0.07 % | $ 2.06 B | ||
|
Evolus
EOLS
|
102 M | $ 6.88 | 0.36 % | $ 427 M | ||
|
Harrow Health
HROW
|
19.8 M | $ 50.08 | -0.16 % | $ 1.63 B | ||
|
China Pharma Holdings
CPHI
|
1.71 M | $ 1.29 | -1.56 % | $ 22.5 M | ||
|
Organogenesis Holdings
ORGO
|
105 M | $ 5.36 | -8.71 % | $ 706 M | ||
|
OrganiGram Holdings
OGI
|
107 M | $ 1.8 | 1.99 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
26.5 B | $ 7.19 | -0.07 % | $ 2.62 B | ||
|
Pacira BioSciences
PCRX
|
368 M | $ 26.48 | 1.77 % | $ 1.22 B | ||
|
Lannett Company
LCI
|
677 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
11.4 M | - | - | $ 193 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
23.9 M | $ 4.11 | -2.14 % | $ 57.8 M | ||
|
Rockwell Medical
RMTI
|
11.6 M | $ 0.87 | 7.18 % | $ 20.3 M | ||
|
Solid Biosciences
SLDB
|
21.2 M | $ 5.83 | -1.19 % | $ 238 M | ||
|
Sundial Growers
SNDL
|
1.03 M | $ 1.75 | -1.13 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
991 K | $ 3.63 | -0.41 % | $ 4.5 M | ||
|
PetIQ
PETQ
|
456 M | - | 1.64 % | $ 400 M | ||
|
Radius Health
RDUS
|
200 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
111 M | - | -4.76 % | $ 65.3 M | ||
|
Jupiter Wellness
JUPW
|
6.38 K | - | - | $ 33.6 M | ||
|
Veru
VERU
|
6.71 M | $ 2.37 | 1.28 % | $ 320 M | ||
|
Perrigo Company plc
PRGO
|
4.28 B | $ 13.87 | 0.95 % | $ 1.91 B | ||
|
ProPhase Labs
PRPH
|
7.94 M | $ 0.51 | -16.94 % | $ 8.08 M | ||
|
Relmada Therapeutics
RLMD
|
2.66 M | $ 4.5 | -2.21 % | $ 135 M | ||
|
cbdMD
YCBD
|
2.49 M | $ 1.69 | 3.68 % | $ 7.29 M | ||
|
OptiNose
OPTN
|
130 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
115 M | $ 9.92 | 0.22 % | $ 705 M | ||
|
PLx Pharma
PLXP
|
34 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
53.4 M | $ 0.58 | -1.87 % | $ 27.8 M | ||
|
Tilray
TLRY
|
570 M | $ 9.6 | -5.43 % | $ 5.93 B | ||
|
TherapeuticsMD
TXMD
|
246 M | $ 1.72 | 0.88 % | $ 18 M | ||
|
Viatris
VTRS
|
13.8 B | $ 12.33 | 0.69 % | $ 14.9 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
110 K | - | - | $ 55.5 M |